Citrine Medicine is a pharmaceutical company and focused on providing effective and affordable therapeutic solutions to rare disease patients in the Greater China. Citrine Medicine currently focuses on 4 therapeutic areas: neurology, endocrinology, liver, kidney & metabolic diseases, and rare oncology. Citrine already has two assets WAKIX® & Alkindi® in pre-NDA stage for rare diseases in neurology and endocrinology, respectively.
  • Therapeutic Area Focus
  • Product Pipeline
  • Therapeutic Area Focus
    People living with a rare disease are at the center of everything we do at Citrine.
    We focus on building access to treatments for the 20 million rare disease patients in China who have very few options available to them. We aim to deliver innovative therapies and to make a positive impact on the lives of patients.We focus on rare neurological, metabolic/endocrine, renal/liver and pediatric oncology diseases.
  • Product Pipeline
    Pitolisant(Wakix®)
    WAKIX® is a narcolepsy treatment that Citrine has in-licensed from the French biotech company, Bioprojet, for use in China.
    WAKIX®(Pitolisant) is the first-in-class novel mechanism H3 receptor antagonist approved by the European Medicines Agency (EMA) in 2016 and by FDA in 2018. It will be the first approved medicine for narcolepsy treatment in China. In the mean time, it has the potential to expand its indication to the treatment of pediatric narcoleptic patients with or without cataplexy and obstructive sleep apnea syndrome.
  • Rare Neurological Diseases
  • Rare Metabolic and Endocrine Diseases
  • Rare Neurological Diseases
    Rare neurological diseases include developmental defects of the nervous system, genetic and metabolic diseases, neuroimmune diseases, neurological tumors, special types of infectious diseases of the nervous system, neurodegenerative diseases, and neuromuscular diseases. At present, more than 7,000 rare diseases have been found in humans, about 60% of which are neurological diseases.
  • Rare Metabolic and Endocrine Diseases
    The endocrine and metabolic system includes endocrine glands and endocrine tissues, which regulate human function by secreting hormones. Endocrine diseases are rare and often very difficult to diagnose and treat. Among the 121 rare diseases included on China’s national list of rare diseases in 2018, more than 20 are endocrine/metabolic-related rare diseases.
  • Rare Liver and Renal Diseases
    Chronic kidney disease (CKD) is a non-communicable disease usually caused by diabetes and hypertension. The prevalence of chronic kidney disease in China is reported to be 10.8%, and is predicted to increase in the next decade, especially among rural regions and certain geographic regions. Liver disease accounts for approximately 2 million deaths per year worldwide, with 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. Specific rare liver and kidney diseases often associated with metabolic syndrome as well as viral hepatitis.
  • Rare Pediatric Oncology Disease
    In recent years, the incidence of childhood cancer has been on the rise, and malignant tumor has become one of the main causes of death among adolescents. More than 250,000 children worldwide are diagnosed with cancer each year, and about 90,000 children die of cancer—making it the leading cause of death among children. In addition to leukemia, malignant lymphoma and other blood tumors, childhood tumors often impact the central nervous system.